Common TitleEPEP
Official Title Safety, Tolerability, and Adherence to Co-formulated Emtricitabine-rilpivirine-tenofovir Used as HIV Nonoccupational Post Exposure Prophylaxis in Men Who Have Sex With Men (EPEP)
Phase Phase IV
ClinicalTrials.gov NCT01715636
Treatments
Rilpivirine-Tenofovir DF-Emtricitabine

Rilpivirine-Tenofovir DF-Emtricitabine
Tradename:CompleraOther Names:RPV-TDF-FTC, Rilpivirine-Tenofovir disoproxil fumarate-EmtricitabineClass:Single-Tablet RegimensCategories PharmacologyAdverse EffectsPEP
Funding
IndustryGilead Sciences
References
- Foster R, McAllister J, Read TR, et al. Single-tablet emtricitabine-rilpivirine-tenofovir as HIV postexposure prophylaxis in men who have sex with men. Clin Infect Dis. 2015;61:1336-41.